Flotation

Cambridge’s gene therapy developer had set terms for an offering set to raise between $135m and $149m on the Nasdaq Global Select Market.

The stem cell-transplant technology developer, partly based on Stanford research, is going public through a reverse merger that will give it a $490m market capitalisation.

Talaris has raised $150m in an initial public offering almost two decades after being spun out of University of Louisville as Regenerx.

The UPMC-backed cancer biotherapeutics developer priced its shares in the middle of their range in its initial public offering.

Vaccitech, which developed the technology underlying Oxford’s covid vaccine, has priced its shares and will raise more than $110m in its IPO.

Yale’s immunological and inflammatory disease therapy developer has filed for an offering with an $86.3m placeholder target.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.